✦ LIBER ✦

The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson's disease: A double blind placebo-controlled pilot study

✍ Scribed by Tanya Gurevich; Chava Peretz; Orna Moore; Nina Weizmann; Nir Giladi

Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 61 KB
Volume: 22
Category: Article
ISSN: 0885-3185
DOI: 10.1002/mds.21396

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Objective

To assess the effect on freezing of gait (FOG) of botulinum toxin type A (BTX‐A) injections in advanced Parkinson's disease (PD) patients.

Method

BTX‐A 150 IU or normal saline was injected into each leg's calf muscles by a blinded investigator. FOG severity was assessed at set intervals (6‐month follow‐up).

Results

Eleven age‐ and disease severity‐matched PD patients with disabling FOG participated. Six patients received BTX‐A and 5 received saline. No improvement was observed in either group over time. Leg weakness and falls lead to early termination.

Conclusion

📜 SIMILAR VOLUMES

Double-blind, placebo-controlled study t

Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism

✍ Francesca Mancini; Roberta Zangaglia; Silvano Cristina; Maria Grazia Sommaruga; 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB 👁 2 views

## Abstract Drooling is a frequent symptom in Parkinson's disease (PD), occurring in almost 75% of all patients. Although it is now well known that drooling in PD is the result of swallowing difficulties rather than excessive saliva production, few treatments have been developed to reduce it. Clini

The effects of rasagiline on cognitive d

The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: A randomized, double-blind, placebo-controlled, multicenter study

✍ Hasmet A. Hanagasi; Hakan Gurvit; Pınar Unsalan; Hilal Horozoglu; Nese Tuncer; A 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 2 views

## Abstract Cognitive impairment can occur at all stages of Parkinson's disease. Rasagiline is a selective monoamine oxidase type‐B inhibitor that enhances central dopaminergic transmission. Dopamine is thought to be involved in certain cognitive processes such as working memory. We assessed the ef

Efficacy and safety of botulinum type A

Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: Results of the first US randomized, double-blind, placebo-controlled study

✍ Daniel Truong; Drake D. Duane; Joseph Jankovic; Carlos Singer; Lauren C. Seeberg 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB

## Abstract Botulinum toxin type A (Dysport) has been shown in European studies to be a safe and effective treatment for cervical dystonia. This multicenter, double‐blind, randomized, controlled trial assessed the safety and efficacy of Dysport in cervical dystonia patients in the United States. Ei

The impact of left prefrontal repetitive

The impact of left prefrontal repetitive transcranial magnetic stimulation on depression in Parkinson's disease: A randomized, double-blind, placebo-controlled study

✍ Endre Pal; Ferenc Nagy; Zsuzsanna Aschermann; Eva Balazs; Norbert Kovacs 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB 👁 2 views

## Abstract Based on several open‐label and case studies, repetitive transcranial magnetic stimulation (rTMS) seems to have an antidepressive effect on patients with Parkinson's disease (PD). However, this hypothesis requires further confirmation. We conducted a randomized, double‐blind placebo‐con

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients

✍ Fabrizio Stocchi; Rupam Borgohain; Marco Onofrj; Anthony H.V. Schapira; Mohit Bh 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 446 KB 👁 2 views

## Abstract Safinamide is an α‐aminoamide with both dopaminergic and nondopaminergic mechanisms of action evaluated as an add‐on to dopamine agonist (DA) therapy in early‐stage PD. In this 24‐week, double‐blind study, patients with early PD receiving a stable dose of a single DA were randomized to

No Effect of the Calcium Antagonist, Isr

No Effect of the Calcium Antagonist, Isradipine, on Plasma Catecholamines in Irreversible Chronic Obstructive Pulmonary Disease (COPD). A Randomized, Double-blind, Placebo-controlled Study

✍ Niels A. Graudal; Anders M. Galløe; Inger Plum; Nils Milman; Jesper O. Clausen 📂 Article 📅 1995 🏛 Elsevier 🌐 English ⚖ 243 KB

SUMMARY: Calcium antagonists have been claimed to decrease the pulmonary artery pressure and increase oxygen uptake and cardiac output in patients with chronic obstructive pulmonary disease (COPD). This should tend to decrease the plasma levels of catecholamines. The purpose of the present study was